Medtronic receives FDA clearance for expanded indication of LINQ II™ insertable cardiac monitor for use in pediatric patients ages 2 and older
Retrieved on:
Tuesday, September 20, 2022
Asystole, Dizziness, Health, Algorithm, Swimming, Chest pain, LINQ, NYSE, Twitter, FDA, Food, Hospital, Cardiac electrophysiology, Washington University in St. Louis, LinkedIn, MRI, Syncope, ICM, Bluetooth, U.S. Securities and Exchange Commission, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Physician, AAA, Pain, St. Louis Children's Hospital, Palpitations, Solution, Magnetic resonance imaging, Artificial intelligence, Atrial fibrillation, Caregiver, Katherine Seley-Radtke, Cardiology, AF, Heart, Security (finance), Parent, Conference, Communication, Veni, vidi, vici, Medical device, Medtronic
DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.
Key Points:
- "The data generated from these small monitors can help us better tailor treatment decisions and ongoing management for our patients."
- The latest-generation device has been implanted in thousands of patients globally since it was first commercialized in 2020.
- Medtronic has been a pioneer in the development of insertable cardiac monitors for more than 20 years; to date, more than 1.7 million patients have received a Medtronic ICM.6
Bold thinking. - Innovative Artificial Intelligence Application Reduces False Pause Alerts while Maintaining Perfect Trye Pause Sensitivity for Insertable Cardiac Monitors.